Carvedilol

Introduction Overview

Generic Name

carvedilol

Brand Name

Coreg, Coreg CR

Dosage Form

Oral tablets and extended-release capsules

Drug Class

Non-cardioselective beta blockers

Pharmacokinetics

Absorption:
Carvedilol is well absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations typically occurring within 1 to 2 hours for immediate-release tablets and about 6 to 8 hours for extended-release capsules (Coreg CR). The bioavailability of carvedilol is approximately 25-30%, largely limited due to significant first-pass hepatic metabolism. Food enhances the extent of absorption and reduces the rate of absorption, which is why carvedilol is recommended to be taken with food to improve tolerability and consistent blood levels. In addition, the extended-release formulation allows a once-daily dosing regimen by providing steady carvedilol plasma concentrations over 24 hours.

Distribution:
Carvedilol is extensively distributed throughout body tissues, binding extensively to plasma proteins (albumin) with approximately 98% protein binding. The drug crosses the blood-brain barrier, which accounts for some of its central nervous system effects such as dizziness and fatigue. Carvedilol has a large volume of distribution (about 1.5–2.2 L/kg), indicating significant tissue uptake. The drug localizes particularly in cardiac and vascular tissues where it exerts its therapeutic effects.

Metabolism:
Carvedilol undergoes extensive hepatic metabolism predominantly by cytochrome P450 enzymes CYP2D6 and CYP2C9. It is subject to stereoselective metabolism, with the R(+) and S(-) enantiomers metabolized differently. The S(-) enantiomer possesses non-selective beta-adrenergic blocking activity, whereas both enantiomers contribute to alpha-1 adrenergic blockade. Metabolism leads to various oxidative metabolites, many of which are inactive or much less active than the parent compound. Due to high hepatic metabolism, patients with liver impairment experience significantly increased plasma concentrations and prolonged half-life.

Elimination:
Carvedilol and its metabolites are primarily excreted via bile into the feces (around 60%) with lesser renal elimination (about 20%). The elimination half-life varies from 6 to 10 hours for immediate-release formulations, but the extended-release capsules have a half-life that supports once-daily dosing. The clearance is reduced in hepatic impairment, mandating dose adjustments in such patients. The metabolites are largely inactive and do not significantly contribute to the pharmacological effect. The elimination kinetics allow for steady plasma levels with twice-daily or once-daily dosing regimens depending on the formulation used.

Dosage Forms

Available Dosage Forms:
Coreg is available as immediate-release tablets and extended-release capsules.
- Immediate-release oral tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg
- Extended-release oral capsules (Coreg CR): 10 mg, 20 mg, 40 mg, 80 mg

Dosages for Adults and Adolescents:
- Heart Failure: Initial dosing typically starts at 3.125 mg twice daily for immediate-release tablets, with gradual titration every 1 to 2 weeks to a target dose of 25 mg twice daily for patients weighing less than 85 kg or 50 mg twice daily for those over 85 kg. The extended-release formulation is dosed once daily, with initial dose commonly 10 mg daily, titrated up to a maximum of 80 mg daily.
- Hypertension: Usual starting dose is 6.25 mg twice daily, increased as needed to control blood pressure, up to doses of 25 mg twice daily.
- Post-Myocardial Infarction: Initiation of therapy often starts at 6.25 mg twice daily, aiming for maintenance doses of 12.5 to 25 mg twice daily.

Specific Patient Populations:
- Hepatic Impairment: Severe liver disease is a contraindication; in mild to moderate impairment, dosing should start at the lowest dose with cautious titration and careful monitoring.
- Elderly Patients: Generally started at low doses due to increased susceptibility to hypotension and bradycardia; extended-release forms offer convenience.
- Pediatric Patients: Coreg is not approved for use in patients younger than 18 years.
- Patients with Bronchospastic Disease: Contraindicated due to potential exacerbation of bronchospasm.
- Patients with Heart Conduction Abnormalities: Should not be used in severe bradycardia, heart block, or sick sinus syndrome without pacemaker support.

These dosage regimens should always be individualized based on patient response, tolerability, and clinical condition.

Mechanism Of Action

Carvedilol is a non-cardioselective beta-adrenergic receptor blocker that also exerts alpha-1 adrenergic receptor antagonism, resulting in combined vasodilation and negative chronotropic and inotropic effects. The beta-blocking action reduces sympathetic nervous system stimulation of the heart, leading to decreased heart rate, myocardial contractility, and oxygen demand.

The non-selective beta-blockade involves antagonism of both beta-1 receptors, primarily in cardiac tissue, and beta-2 receptors located in bronchial and vascular smooth muscle. This results in decreased cardiac output and inhibition of renin release from juxtaglomerular cells, contributing to antihypertensive effects.

Carvedilol's alpha-1 blockade results in vasodilation by relaxing vascular smooth muscle, which decreases peripheral vascular resistance and thus lowers blood pressure without significant reflex tachycardia. This dual blockade is clinically beneficial in heart failure patients where excessive vasoconstriction and sympathetic overactivity are detrimental.

At the cellular level, carvedilol has antioxidant properties that may protect cardiac myocytes from oxidative stress-related damage seen in heart failure. Additionally, experimental studies suggest it may inhibit cardiac remodeling by modulating signaling pathways involved in fibrosis and apoptosis, thereby improving myocardial structure and function.

Compared to selective beta-1 blockers (e.g., metoprolol), carvedilol’s non-selective beta and alpha-1 antagonism provide a broader spectrum of cardiovascular effects, which may translate into improved outcomes in heart failure and hypertension as demonstrated in clinical trials. Its efficacy in reducing morbidity and mortality post-myocardial infarction and in chronic heart failure has been validated by numerous large-scale randomized controlled studies.

Pharmacological Actions

Non-selective blockade of beta-1 and beta-2 adrenergic receptors reducing heart rate and myocardial contractility.
Alpha-1 adrenergic receptor antagonism causing peripheral vasodilation and decreased systemic vascular resistance.
Reduction of renin release from juxtaglomerular renal cells, decreasing angiotensin II production.
Antioxidant properties protecting cardiac cells from oxidative injury.
Modulation of cardiac remodeling processes, including fibrosis and apoptosis inhibition.
Decrease in myocardial oxygen demand through combined chronotropic and inotropic effects.
Improvement of left ventricular ejection fraction in systolic heart failure.
Blunting of sympathetic nervous system hyperactivity leading to improved clinical outcomes.
Suppression of arrhythmogenic potential by stabilizing cardiac electrical activity.
Reduction in peripheral edema through vasodilatory effects when combined with other heart failure therapies.
Attenuation of abnormal vascular smooth muscle proliferation.
No significant intrinsic sympathomimetic activity, providing sustained beta-blockade.
Limited central nervous system penetration compared to other beta-blockers, reducing CNS side effects.
Potential stabilization of endothelial function contributing to antihypertensive effects.
No significant alteration in lipid profiles unlike some other beta-blockers.

Therapeutic Or Clinical Uses

Management of chronic heart failure with reduced ejection fraction to improve survival and decrease hospitalizations.
Treatment of hypertension as monotherapy or in combination with other antihypertensive agents.
Post-myocardial infarction therapy to reduce mortality in patients with left ventricular systolic dysfunction.
Control of angina pectoris through reduction of myocardial oxygen demand.
Off-label use in certain arrhythmias for rate control.
Protection against cardiac remodeling following myocardial injury.
Management of essential tremor in selected patients due to beta-blocking effects.
Adjunct therapy in hypertrophic cardiomyopathy to decrease heart rate and improve symptoms.
Use in portal hypertension and prevention of variceal bleeding in cirrhotic patients (off-label).
Reduction of sympathetic symptoms related to hyperthyroidism (off-label).
Treatment of migraine prophylaxis in certain clinical settings.
Reduction of perioperative cardiovascular risk in patients undergoing non-cardiac surgery.
Management of pheochromocytoma preoperatively after alpha-blockade is established.
Adjunctive therapy in Raynaud's phenomenon to reduce vasospasm.
Use in pediatric patients is not approved but has been studied off-label under specialist guidance.

Side Or Adverse Effects

Dizziness and lightheadedness due to blood pressure lowering and decreased heart rate.
Bradycardia and heart block, potentially requiring dose adjustment or discontinuation.
Fatigue, weakness, and exercise intolerance from decreased cardiac output.
Hypotension, especially during initiation or titration.
Weight gain related to fluid retention in some heart failure patients.
Diarrhea and gastrointestinal disturbances.
Cold extremities, numbness, or worsening of peripheral circulation (Raynaud’s phenomenon).
Worsening symptoms of asthma or chronic obstructive pulmonary disease due to beta-2 blockade.
Dry eyes and problems with contact lens tolerance.
Hyperglycemia or masking of hypoglycemia symptoms in diabetic patients.
Sexual dysfunction including decreased libido or erectile dysfunction.
Potential for agranulocytosis or other hematologic abnormalities (rare).
Allergic reactions including rash, urticaria, or angioedema.
Sleep disturbances including vivid dreams or insomnia.
Severe side effects such as heart failure exacerbation or bronchospasm requiring medical attention.

Precautions

Use cautiously in patients with asthma or chronic obstructive pulmonary disease due to risk of bronchospasm.
Avoid abrupt discontinuation to prevent rebound hypertension, angina, or myocardial infarction.
Monitor blood pressure and heart rate frequently during dose titration.
Use with caution in patients with diabetes mellitus as carvedilol may mask hypoglycemia symptoms.
Careful dose adjustment in patients with hepatic impairment due to decreased metabolism and increased plasma levels.
Assess cardiac conduction system status before initiation; contraindicated in severe bradycardia or heart block without pacemaker.
Use caution in patients with peripheral vascular disease; may worsen symptoms of Raynaud's phenomenon.
Avoid alcohol consumption close to time of dosing of extended-release capsules to prevent dose dumping.
Dose adjustment and close monitoring required in elderly due to increased sensitivity to hypotension and dizziness.
Pregnancy and breastfeeding should be evaluated carefully; use only if potential benefit justifies potential risk.
Inform patients about possible dizziness and avoid hazardous activities until stable.
Monitor for signs of worsening heart failure especially during initiation or dose changes.
Be cautious in patients with thyroid disorders due to altered sensitivity to beta-blockade.
Medication adherence is critical for therapeutic efficacy and prevention of adverse cardiovascular events.
Evaluate concomitant medications thoroughly to avoid interactions and additive effects.

Warnings

Contraindicated in patients with asthma, bronchitis, or emphysema due to potential for severe bronchospasm.
Should not be used in patients with severe liver disease because of prolonged drug clearance and toxicity risk.
Avoid in patients with severe bradycardia, heart block, or sick sinus syndrome unless pacemaker is present.
Patients should not discontinue therapy abruptly to avoid exacerbation of angina or precipitating myocardial infarction.
Alcohol consumption should be avoided within 2 hours before or after taking Coreg CR to prevent rapid drug release and toxicity.
May cause hypotension leading to dizziness, syncope, or falls, especially in elderly or volume-depleted patients.
Use with caution in patients with congestive heart failure; monitor closely for worsening symptoms.
May mask typical signs of hypoglycemia in diabetic patients, complicating diabetes management.
Severe allergic reactions may occur; patients should seek immediate medical attention if signs arise.
May exacerbate peripheral vascular disease or Raynaud’s phenomenon causing ischemic symptoms.
Concomitant use with other medications affecting conduction may potentiate bradycardia or heart block.
Caution in patients undergoing surgery, as beta-blockade may affect cardiovascular responses.
Can cause weight gain and fluid retention necessitating monitoring in heart failure patients.
Use during pregnancy only if clearly needed due to potential fetal risks.
Patients should be advised to report any unusual symptoms such as severe fatigue, swelling, or respiratory distress promptly.

Contraindication

Known hypersensitivity or allergy to carvedilol or any component of the formulation.
Asthma, bronchospasm, or other chronic obstructive pulmonary diseases with active bronchiolar constriction.
Severe hepatic impairment due to risk of accumulation and toxicity.
Severe bradycardia (heart rate < 50 bpm) without pacemaker support.
Second- or third-degree atrioventricular (AV) block or sick sinus syndrome without pacemaker.
Cardiogenic shock or decompensated heart failure requiring intravenous inotropic therapy.
Severe hypotension or uncontrolled heart failure.
Unstable or uncompensated cardiac conditions such as acute heart failure exacerbation.
Severe peripheral arterial circulatory disorders with ischemic manifestations.
Hypersensitivity to other beta blockers may be a relative contraindication depending on clinical judgment.
Caution or contraindication in patients with pheochromocytoma unless adequate alpha-blockade is established first.
Use prudently or avoid in patients with significant sinus node dysfunction unless pacemaker is implanted.

Drug Interactions

Calcium channel blockers (e.g., verapamil, diltiazem) may potentiate bradycardia and atrioventricular block when co-administered with carvedilol.
Concurrent use with other antihypertensive agents can have additive blood pressure-lowering effects, increasing risk of hypotension.
Drugs that inhibit cytochrome P450 enzymes (especially CYP2D6 inhibitors such as fluoxetine or paroxetine) can increase carvedilol plasma concentrations.
Co-administration with insulin or oral hypoglycemic agents can mask signs of hypoglycemia and potentiate blood glucose alterations.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive efficacy of carvedilol.
Digoxin levels may be increased when combined with carvedilol, necessitating monitoring for digoxin toxicity.
Additive negative inotropic or chronotropic effects may occur with other beta-blockers or antiarrhythmics.
Clonidine withdrawal combined with carvedilol requires careful management to avoid rebound hypertension.
Alcohol can increase hypotensive effect and CNS adverse effects of carvedilol; alcohol should be avoided close to dosing, especially with extended-release capsules.
Catecholamine-depleting drugs or sympatholytics may increase risk of bradycardia or hypotension.
Phenytoin and rifampin may increase carvedilol metabolism, reducing efficacy.
Concomitant use with cimetidine may increase carvedilol plasma concentration.
Sympathomimetic agents can reduce the effectiveness of carvedilol by competing for adrenergic receptors.
Combination with amiodarone may increase risk of bradycardia and cardiac conduction disturbances.
Co-administration with drugs causing QT prolongation should be done with caution.

Preparations Of The Drug

Immediate-release tablets available in strengths of 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg for twice-daily dosing.
Extended-release (Coreg CR) capsules available in 10 mg, 20 mg, 40 mg, and 80 mg formulations for once-daily dosing.
Tablets are for oral administration and should be taken with food to reduce orthostatic hypotension and enhance absorption.
Extended-release capsules should be swallowed whole; if unable to swallow, capsules may be opened and sprinkled on a small amount of cold applesauce and taken immediately without chewing.
Solutions or injectables are not commercially available; oral tablets and capsules are the standard formulations.
Generic carvedilol is widely available in both immediate and extended-release oral forms.
Packaging typically includes blister packs or bottles with child-resistant caps to ensure safety.
Storage requires room temperature conditions away from moisture and heat to maintain drug stability.
No topical or parenteral formulations are available for carvedilol; only oral dosage forms approved.
Patient education materials often emphasize adherence, proper dosing time with meals, and not discontinuing therapy abruptly.
Supply sizes vary from small quantities for initiation and titration to larger maintenance dosing supplies.
Combination products of carvedilol with other antihypertensives are generally not available; it is used as monotherapy or in combination with separate agents.
Labeling includes detailed instructions on titration schedules, side effects, and contraindications.
Formulations without lactose or gluten are available to accommodate specific patient needs.
Coreg CR offers improved compliance due to once-daily dosing and smoother pharmacokinetic profiles.